国家与国际子宫肌瘤管理指南的系统评价
最高分指南为RANZOG 2001(56.5%),无指南达到高质量标准(≥66%)。共166条推荐,仅3个领域达成共识,27.7%推荐仅基于专家意见。
要点
- 现有子宫肌瘤指南质量均未达高质量标准(AGREE-II评分≥66%)
- 仅3个领域达成共识,存在多个争议领域如醋酸乌利司他和旋切术
- 27.7%的推荐仅基于专家意见,缺乏支持证据
核心结论
- 当前国家子宫肌瘤指南使用AGREE工具评估存在质量缺陷,需要高质量指南以应对肌瘤异质性和治疗多样性。
主要发现
- 共评估8部国家指南(AAGL、SOGC 2014、ACOG、ACR、SOGC 2019、CNGOF、ASRM和SOGC 2015)和1部国际指南(RANZOG)。
- 最高分指南为RANZOG 2001,得分56.5%;无指南达到高质量标准(≥66%)。
- 指南共包含166条推荐,仅3个领域达成共识,多个领域存在分歧和不确定性。
- 27.7%的推荐仅基于专家意见,许多推荐缺乏支持证据。
关键数值与推荐
- 高质量指南的预先设定标准为AGREE-II总体评分≥66%。
- 最高分指南RANZOG 2001得分为56.5%。
- 27.7%的推荐仅基于专家意见。
临床怎么用
- 临床医生应知晓现有子宫肌瘤指南方法学质量不足,在决策时需谨慎结合个体情况。
- 对于争议领域如醋酸乌利司他和旋切术,应关注最新证据而非完全依赖指南。
局限性
- 仅纳入英文发表的指南,可能遗漏其他语种指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines standardise high-quality evidence-based management strategies for clinicians. Uterine fibroids are a highly prevalent condition and may exert significant morbidity. OBJECTIVES: To appraise national and international uterine fibroid guidelines using the validated AGREE-II instrument. SELECTION STRATEGY: Database search of PubMed and EMBASE from inception to October 2020 for all published English-language uterine fibroid clinical practice guidelines. DATA COLLECTION AND ANALYSIS: In all, 939 abstracts were screened for eligibility by two reviewers independently. Three reviewers used the AGREE-II instrument to assess guideline quality in six domains. Recommendations were mapped to allow a narrative synthesis regarding areas of consensus and disagreement. MAIN RESULTS: Eight national guidelines (AAGL, SOGC 2014, ACOG, ACR, SOGC 2019, CNGOF, ASRM and SOGC 2015) and one international guideline (RANZOG) were appraised. The highest scoring guideline was RANZOG 2001(score 56.5%). None of the guidelines met the a priori criteria for being high-quality overall (score ≥66%). There were 166 recommendations across guidelines. There were several areas of disagreement and uncertainty. There were only three areas of consensus. Supporting evidence was not evident for many recommendations; 27.7% of recommendations were based on expert opinion only. CONCLUSIONS: There is a need for high-quality guidelines on fibroids given their heterogeneity across individuals and the large range of treatment modalities available. There are also areas of controversy in the management of fibroids (e.g. Ulipristal acetate, power morcellation), which should also be addressed in any guidelines. Future guidelines should be methodologically robust to allow high-quality decision-making regarding fibroid treatments. TWEETABLE ABSTRACT: Current national fibroid guidelines have deficiencies in quality when appraised using the validated AGREE instrument.
引用
- Amoah A, Joseph N, Reap S, et al. Appraisal of national and international uterine fibroid management guidelines: a systematic review. BJOG. 2021. PMID: 34532956. doi:10.1111/1471-0528.16928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。